{"preliminary_commentary":{"by_channel":{"x_thread":18,"youtube":11,"podcast":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03867084\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"KEYNOTE-937","nct_id":"NCT03867084","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-937-nct03867084. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive intravenous (IV) pembrolizumab at 200 mg on Day 1 of each 21-day cycle for up to 17 cycles.","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive IV placebo on Day 1 of each 21-day cycle for up to 17 cycles.","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-09-30","type":"ACTUAL"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":959,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-24","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-03-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recurrence-Free Survival (RFS)","timeFrame":"Up to approximately 69 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 69 months"}],"references":[{"citation":"Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022 Jun 13;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807.","pmid":"35421228","type":"DERIVED"}],"start_date":{"date":"2019-05-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)","url":"https://clinicaltrials.gov/study/NCT03867084"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-937-nct03867084"}